GSK, OncoMethylome Investigating Methylation Markers in Immunotherapy Program

Although OncoMethylome could not disclose the specific drug development program for which its DNA methylation-specific PCR biomarker will be used, GSK's pipeline offers some hints as to the specific immunotherapeutic involved.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.